SET2,3
DEAD

Serial Number

90864949

Owner

Delphi Diagnostics, Inc.

Attorney

Christopher Turk

Filing Date

Aug 4, 2021

Add to watchlist:

No watchlists yet
View on USPTO

SET2,3 Trademark

Serial Number: 90864949

SET2,3 is a trademark filed by Delphi Diagnostics, Inc. on August 4, 2021. The trademark is classified under Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 45 (Legal & Security Services). The application is currently no longer active.

Owner Contact Info

Delphi Diagnostics, Inc. (10 trademarks)

PO Box 341449
Austin, TX 78734

Entity Type: 03

Trademark Details

Filing Date

August 4, 2021

Registration Date

Not Registered

Published for Opposition

June 7, 2022

Goods & Services

Biological preparations for the treatment of cancer; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; Anti-cancer preparations; Protein arrays for diagnosing cancer

Providing a website via a global computer network featuring supportive personal stories on the subjects of health, cancer, cancer recovery and survival

Medical testing for diagnostic, prognosis and treatment purposes in the field of cancer research and disease classification; Providing medical information to medical professionals in the field of cancer and disease classification; Providing medical information to medical professionals on sensitivities of cancers to hormones and/or hormone therapies

Medical apparatus for detecting cancer; Medical device for detecting cancer; Medical diagnostic apparatus for testing cancer cells incorporating recorded operating system software; Medical nanites for treating cancer; Medical nanorobots for treating cancer; Medical microrobots for treating cancer

Medical and scientific research in the field of cancer treatment and diagnosis; Medical research services in the field of cancer; Providing laboratory research services in the field of gene expression, namely, cancer biology; Research and development of pharmaceuticals for the treatment of age-related diseases and cancer; Medical diagnosis and treatment of cancer; Providing information about medical research in the field of cancer

Filing History

ABANDONMENT NOTICE E-MAILED - INTER PARTES DECISION
Feb 2, 2023 MAB4
ABANDONMENT - AFTER INTER PARTES DECISION
Feb 2, 2023 ABN4
OPPOSITION TERMINATED NO. 999999
Feb 2, 2023 OP.T
OPPOSITION SUSTAINED NO. 999999
Feb 2, 2023 OP.S
OPPOSITION INSTITUTED NO. 999999
Jul 27, 2022 OP.I
EXTENSION OF TIME TO OPPOSE RECEIVED
Jul 5, 2022 ETOF
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jun 7, 2022 NPUB
PUBLISHED FOR OPPOSITION
Jun 7, 2022 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
May 18, 2022 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
May 3, 2022 CNSA
ASSIGNED TO EXAMINER
May 3, 2022 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 29, 2021 NWOS
NEW APPLICATION ENTERED
Aug 7, 2021 NWAP